pharmaphorum

SEPTEMBER 2, 2020

While the effects of COVID-19 have been devastating for many industries, its positive impact on accelerating the uptake of digital health technologies and virtual collaboration solutions is undeniable. This has been a long time coming and there are countless reasons why I believe virtual collaboration and medical education are here to stay, long after there is a vaccine for COVID-19 and physical distancing guidelines have been lifted. 1.

Communication 128

Communication Vaccines 128

Outsourcing Pharma

SEPTEMBER 3, 2020

Innovative research by Tabula Rasa Healthcare uses simulation technology to analyze potential adverse drug events of potential therapies for the virus.

96

96

Pharma Mirror

SEPTEMBER 4, 2020

The first digital session of Medical Device Innovation Summit concludes on a positive note with industry leaders addressing burning topics to promote innovation in the medical equipment industry. From challenges like lack of regulatory systems to its new found potential of manufacturing indigenous products on a large scale, the summit successfully addressed discussions on new.

80

80

Druggist

SEPTEMBER 1, 2020

Without a doubt, Imodium is the most popular brand used as diarrhoea relief medication. Today’s post focuses on Imodium alternative drugs for the relief of diarrhoea. Causes of diarrhoea Diarrhoea is a common condition, which can affect children and adults of any age. A ‘stomach bug’ often causes acute diarrhoea, but an underlying condition and drugs can also cause it.

Generic Medicine 59

Generic Medicine 59

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

pharmaphorum

SEPTEMBER 2, 2020

The UK’s medicines regulator has published long-awaited guidance on regulation of medicines and medical devices as the UK approaches the end of its Brexit transition period at the end of the year. This would see the UK mirroring decisions made by the European Medicines Agency, while also laying out a process should companies wish to file for a separate approval in the UK.

Documentation 124

Documentation Labelling 124

Outsourcing Pharma

AUGUST 31, 2020

A recent study from healthcare insights company Sermo shares information and perspectives that trial and pharma professionals could learn from.

93

93

Pharma Mirror

SEPTEMBER 2, 2020

Jacobson Pharma Corporation Limited (“Jacobson Pharma” or the Group”; Stock Code: 2633.HK), a leading company engaged in the research, development, production, marketing and sale of essential medicines and branded healthcare products in Hong Kong, announced the signing of a letter of intent (“Letter of Intent”) with Fosun Industrial Co.

Vaccines 52

Vaccines 52

pharmaphorum

SEPTEMBER 2, 2020

Digital health firm Mobio Interactive has closed a $1.8 million seed fund to advance development of its meditation app Am Mindfulness. Mobio said that the app, known as Am for short, is the first and only meditation app to outperform placebo in randomised controlled trials. MI’s Seed raise was led by the Singapore-based Verge HealthTech Fund along with Atlas Asset Management , Creative Ventures and VC giant SOSV.

122

122

Outsourcing Pharma

SEPTEMBER 1, 2020

A new scientific report offers a comprehensive review of protein targets, associated COVID-19 drug candidates to date and other revealing information.

73

73

Pharma Times

SEPTEMBER 3, 2020

Scientists have discovered that hard-to-treat pancreatic cancer hijacks a key immune system response

Immunization 56

Immunization 56

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharma Marketing Network

SEPTEMBER 1, 2020

Despite the COVID-19 pandemic, digital display advertising will continue to grow this year with more investments in video ads. According to eMarketer, U.S. advertisers will increase investments in video by 11.3% this year to $35.45 billion, making it the only digital ad format to grow at a double-digit rate this year. For the first time ever, video will account for more than a quarter of all U.S. digital ad spending.

52

52

pharmaphorum

SEPTEMBER 3, 2020

UK biotech Compass Pathways is planning a $100 million US IPO as it seeks to further develop its depression treatment based on psilocybin – an active ingredient that can be found in magic mushrooms. In a filing with the US financial regulator Compass laid out its plans to develop the drug known as COMP360, which is a crystalline formulation of psilocybin in phase 2b clinical development in patients who have not responded to standard therapy for depression.

Controlled Substances 116

Controlled Substances FDA 116

Outsourcing Pharma

SEPTEMBER 3, 2020

A company leader outlines the importance of increasing diversity in clinical trial patient populations, and how researchers can improve their results.

67

67

Pharma Times

SEPTEMBER 2, 2020

The decision allows use of the therapy in the EU in children as young as six years of age

51

51

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Med Ed 101

SEPTEMBER 2, 2020

Drug food interactions are common and there can be significant negative consequences from these interactions. A common misconception amongst healthcare professionals who may not have as much experience with drug interactions is that ALL statins interact with grapefruit juice. I have heard and read this type of comment before, and it is not true. Grapefruit […].

40

40

pharmaphorum

SEPTEMBER 3, 2020

NICE has rejected regular NHS funding for Janssen’s depression spray Spravato (esketamine) for a second time, although the company says it could salvage the situation by providing further data and “additional discussions”. This will likely see the company drop its price further after already offering a commercially confidential discount to the NHS following European approval late last year.

115

115

Outsourcing Pharma

SEPTEMBER 3, 2020

The companies will join forces to use IntelGenxâs polymeric film technologies for development of pharmaceutical-grade psychedelic drug treatments.

60

60

Pharma Times

SEPTEMBER 1, 2020

Clinical development of AZD1222 is progressing globally with late-stage clinical trials ongoing in the UK, Brazil and South Africa

Vaccines 50

Vaccines 50

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Med Ed 101

AUGUST 30, 2020

If you are a healthcare professional, inevitably, questions about the use of antidepressants in pregnancy come up in clinical practice. Why is paroxetine generally avoided in pregnancy? The primary reason that paroxetine is avoided in pregnancy is that it has demonstrated fetal risks. Through the previous FDA rating system, it was considered an FDA pregnancy […].

FDA 40

FDA 40

pharmaphorum

SEPTEMBER 3, 2020

GlaxoSmithKline is opening a £10 million artificial intelligence (AI) research hub in King’s Cross, London, according to a press report. The area is being reimagined as a life sciences and technology hub and is already home to the Francis Crick Institute biomedical research organisation. King’s Cross is also home to Google’s DeepMind artificial intelligence company, which has already been involved in life sciences projects such as using the technology to predict acute kidney injury.

114

114

Outsourcing Pharma

AUGUST 31, 2020

The company intends to enable pharma and biotech companies to have greater access to cryo-electronic microscopy for their research projects.

59

59

Pharma Times

SEPTEMBER 3, 2020

NICE has concerns with the evidence submitted but Janssen insists the nasal spray is a cost-effective use of NHS resources

50

50

pharmaphorum

SEPTEMBER 2, 2020

Cancer immunotherapy has set new standards in care, with some impressive responses in those patients lucky enough to respond. But many patients still do not respond to therapies such as Merck & Co’s anti PD-1 therapy Keytruda (pembrolizumab), or go on to develop progressive disease, and pharma companies are looking for new second-line therapies.

Immunization 111

Immunization 111

pharmaphorum

SEPTEMBER 1, 2020

Sanofi has drawn another blank in its attempt to repurpose its IL-6 drug Kevzara to tackle the extreme immune reaction seen in serious cases of COVID-19. The French pharma and development partner Regeneron have been testing Kevzara (sarilumab) in patients severely or critically ill and hospitalised with COVID-19. In severe cases of COVID-19, patients suffer a “cytokine storm” where the immune system becomes overstimulated and attacks the body.

Immunization 111

Immunization Hospitals 111

pharmaphorum

SEPTEMBER 4, 2020

Sanofi and GlaxoSmithKline have begun clinical trials of their coronavirus vaccine, as AstraZeneca expanded studies of its rival into Japan. The French pharma in April joined forces with the UK’s GSK to produce the vaccine, with Sanofi contributing an antigen that produces the immune reaction. Meanwhile GSK is producing the booster that reduces the amount of active ingredient necessary to produce an effect.

Vaccines 106

Vaccines Immunization 106

pharmaphorum

SEPTEMBER 3, 2020

Sarah Rickwood looks at how COVID-19 is changing pharma’s commercial models and launch strategies. The terrible pandemic crisis we’ve had as our daily companion for six months is far from over, in part because it is in fact not one crisis, but three. There’s the initial pandemic crisis, which wreaked havoc on communities and stretched urgent care systems to the brink; the consequent healthcare system crisis, where the knock-on effects of the pandemic are still playing out in non-COVID patients a

Pharmaceutical Companies 97

Pharmaceutical Companies Pharmaceutical Companies 97

pharmaphorum

SEPTEMBER 4, 2020

England is to trial population testing for COVID-19 in places such as schools, colleges and busy public spaces. Health secretary Matt Hancock said the government has earmarked an extra £500 million ($552 million) to scale up testing and capacity to launch community pilots as fears mount about as second wave of infections during the winter months. The population testing will be made possible by new test kits capable of giving results within 15 minutes or so.

Hospitals 86

Hospitals Vaccines 86

pharmaphorum

SEPTEMBER 2, 2020

Gilead has joined forces with biotech Jounce Therapeutics to licence its immunotherapy JTX-1811 in a deal worth more than $800 million. The drug, JTX-1811, is a monoclonal antibody designed to selectively deplete immunosuppressive tumour-infiltrating T regulatory (TITR) cells. . The drug targets CCR8, a chemokine receptor enriched on TITR cells. When JTX-1811 binds to CCR8, it targets TITR cells for depletion by an enhanced antibody-dependent cellular cytotoxicity mechanism. .

Immunization 71

Immunization 71

pharmaphorum

SEPTEMBER 2, 2020

Bilal Babar from THE PLANNING SHOP tells us how the movement of birds and Swarm Technology have helped develop multiple market research tools. Flocks of birds wheeling, swooping and gliding in unison, as if choreographed, are a wonderful sight. The benefit to members of the flock are many including safety from predators, more eyes to spot food and natural selection – those that can’t keep up or fly in a very densely populated flock and make such sharp turns without colliding don’t survive.

Communication 71

Communication Pharmaceutical Companies Pharmaceutical Companies 71

pharmaphorum

SEPTEMBER 1, 2020

AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups. The UK pharma said that the trial will recruit up to 30,000 adults aged 18 years or over to assess the safety, efficacy and immune response. AZ already has late-stage trials ongoing in the UK, Brazil and South America, with trials planned to start in Japan and Russia, recruiting up to 50,000 patients globally.

Vaccines 69

Vaccines Immunization 69

pharmaphorum

SEPTEMBER 4, 2020

Leela Barham asks why companies may choose to not submit their drugs to NICE and keep them off routine commissioning – a trend that appears to be on the rise. Appraisal of a treatment by the National Institute for Health and Care Excellence (NICE) is voluntary; companies can simply choose not to submit, resulting in a statement from NICE that the appraisal was terminated due to non-submission.

64

64

pharmaphorum

SEPTEMBER 1, 2020

Novo Nordisk has launched its type 2 diabetes pill Rybelsus (semaglutide) in the UK, after cost-effectiveness watchdog NICE decided that there was no need to review it. After EU approval in April Novo said it had priced Rybelsus at parity with rival GLP-1 drugs in the UK, and NICE will not perform a single technology appraisal as a result, allowing the company to begin negotiations in England and Wales to get the drug included on NHS formularies.

Adverse Reactions 64

Adverse Reactions 64

pharmaphorum

SEPTEMBER 3, 2020

The Canadian government has reached agreements in principle with J&J and Novavax to buy their coronavirus vaccine candidates. Under the agreement with J&J, Canada would purchase up to 38 million doses of Janssen’s Ad26.COV2.S vaccine candidate on a not-for-profit basis for emergency pandemic use. Meanwhile, Novavax has agreed to supply up to 76 million doses of its candidate in the event of the vaccine gaining approval in the country.

Vaccines 61

Vaccines 61